<DOC>
	<DOCNO>NCT02954237</DOCNO>
	<brief_summary>The purpose study observe safety effectiveness AMPLATZER™ Cardiac Plug ( ACP ) device Chinese population indicate use AMPLATZER™ Cardiac Plug market approval China FDA ( CFDA ) . This prospective , multi-centre , single arm , post approval , observational study . The clinical study conduct 35 site China . Approximately 343 subject enrol study . The total study duration expect approximately 7 year . Patients non-valvular atrial fibrillation ( NVAF ) contraindicate long-term oral anticoagulant ; patient experience stroke thromboembolic event despite take warfarin . Scheduled office visit occur ( 45 days+ 2 week ) , 6M ( +/- 3 week ) 12M ( +/- 6 week ) 24 M ( +/- 6 week ) post procedure ; Phone contact follow visit occur , 36 M ( +/- 6 week ) , 48M ( +/- 6 week ) 60 M ( +/- 6 week ) post procedure .</brief_summary>
	<brief_title>AMPLATZER™ Cardiac Plug Observational Post-Approval Study ( ACP PAS China )</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>1 . 1 . Patient meet current indication per physician discretion ACP implant 2 . Patient ≥ 18 year age time enrolment . 3 . Patient able provide write Informed Consent prior study related procedure . 2 . 1 . Patient unable comply followup schedule . 2 . Patient presence intracardiac thrombus 3 . Patient active endocarditis infection produce bacteraemia 4 . Patient low risk stroke ( CHA2DS2VASC score 0 1 ) low risk bleeding ( HASBLED score &lt; 3 ) 5 . Patient placement device would interfere intracardiac intravascular structure 6 . Patient medical condition appropriate participate study opinion investigator 7 . Subject LAA anatomy accommodate device per size guideline 8 . Patient life expectancy le 2 year due condition . 9 . Patient already expose another investigational product 10 . Patient already leave atrial appendage closure device implant prior study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Non-valvular atrial fibrillation ( NVAF )</keyword>
	<keyword>Anticoagulant</keyword>
	<keyword>Warfarin</keyword>
	<keyword>Stroke</keyword>
</DOC>